Business
ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, announced four G-Rex Grants have been awarded to faculty members at Children's National Hospital. The funding, totaling $375,000, will support the optimization and translation of various cell and gene therapy initiatives into the clinic.
About this update from Bio-techne Corp
[{"type":"text","content":"ST. PAUL, Minn., Oct. 23, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, announced four G-Rex Grants have been awarded to faculty members at Children's National Hospital. The funding, totaling $375,000, will support the optimization and translation of various cell and gene therapy initiatives into the clinic.","length":402,"tagName":"p"},{"type":"text","content":"Dr. Patrick Hanley, Chief & Director of Cell Therapy, received a $100,000 G-Rex Grant to develop a G-Rex centric CAR-T cell manufacturing process as a nimble, flexible, and cost-effective alternative to their current approach that relies on complex and expensive capital equipment.","length":285,"tagName":"p"},{"type":"text","content":"Dr. Michael Keller, Translational Research Laboratory – CETI Director, and Dr. Hanley, were co-recipients of a $150,000 G-Rex Grant to support the optimization of their current Virus Specific T cell (VST) and Tumor Antigen Associate T cell (TAAT) manufacturing processes, by transitioning into the optimized G-Rex "M" series bioreactors for functionally closed and semi-automated production. This will help minimize touchpoints and streamline VST and TAAT manufacturing.","length":480,"tagName":"p"},{"type":"text","content":"Dr. Amy Hont, Oncologist in Pediatric Hematology, received a $75,000 G-Rex Grant to support process development and implementation of closed system G-Rex manufacturing of their novel ATTACK TAAT cell therapy for the treatment of various solid tumors.","length":250,"tagName":"p"},{"type":"text","content":"Dr. Conrad Russell Cruz, Principal Investigator, received a $50,000 G-Rex Grant to support process development and optimization of a G-Rex centric process for manufacturing CAR-modified TAAT cells for treatment of various solid tumors.","length":235,"tagName":"p"},{"type":"text","content":""This effort reflects the importance of working together to move promising cell and gene therapies from the lab to the patients who need them most. We're thankful for the support and eager to continue this important work," said Dr. Hanley.","length":253,"tagName":"p"},{"type":"text","content":""Children's National has been a leader in pediatric cell and gene-modified cell therapies (CGT) for many years. Having b...